Clinical Trial Update: Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of a folate receptor alpha peptide vaccine with GM-CSF in patients with breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Folate receptor alpha peptide vaccine with GM-CSF

Snippet

Sponsor: Marker Therapeutics, Inc. | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED